CERo Therapeutics Holdings, Inc. Common Stock Total Assets
CERo Therapeutics Holdings, Inc. Common Stock total assets. Based on the latest financial reports, CERo Therapeutics Holdings, Inc. Common Stock (CERO) holds total assets worth $1.90 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CERO stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of CERo Therapeutics Holdings, Inc. Common Stock (2021–2025)
Total assets of CERo Therapeutics Holdings, Inc. Common Stock from 2021 to 2025. This chart illustrates how CERo Therapeutics Holdings, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See CERO share price today for real-time trading data and today's change.
CERo Therapeutics Holdings, Inc. Common Stock - Asset Composition Analysis
CERo Therapeutics Holdings, Inc. Common Stock Total Assets Breakdown (December 2025)
CERo Therapeutics Holdings, Inc. Common Stock total assets breakdown as of December 2025. CERo Therapeutics Holdings, Inc. Common Stock's total assets of $1.90 Million consist of 75.1% current assets and 24.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how CERo Therapeutics Holdings, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore CERO working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CERo Therapeutics Holdings, Inc. Common Stock's current assets represent 75.1% of total assets in 2025, an increase from 0.8% in 2021.
- Cash Position: Cash and equivalents constituted 45.7% of total assets in 2025, up from 0.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
CERo Therapeutics Holdings, Inc. Common Stock Competitors by Total Assets
Key competitors of CERo Therapeutics Holdings, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €2.00 Billion |
|
Abivax SA
PA:ABVX
|
France | €547.14 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Disc Medicine Inc.
NASDAQ:IRON
|
USA | $735.07 Million |
|
Alpha Tau Medical Ltd
NASDAQ:DRTS
|
USA | $104.69 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
CERo Therapeutics Holdings, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.05 | 0.56 | 0.09 |
| Quick Ratio | 0.05 | 0.56 | 0.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-30.86 Million | $-3.37 Million | $-253.00K |
CERo Therapeutics Holdings, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between CERo Therapeutics Holdings, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | -41.3% |
| Total Assets | $3.64 Million |
| Market Capitalization | $716.31K USD |
Valuation Analysis
Below Book Valuation: The market values CERo Therapeutics Holdings, Inc. Common Stock's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: CERo Therapeutics Holdings, Inc. Common Stock's assets decreased by 41.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for CERo Therapeutics Holdings, Inc. Common Stock (2021–2025)
The table below shows the annual total assets of CERo Therapeutics Holdings, Inc. Common Stock from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $3.64 Million | -41.34% |
| 2024-12-31 | $6.21 Million | +21.08% |
| 2023-12-31 | $5.13 Million | -87.90% |
| 2022-12-31 | $42.37 Million | -76.47% |
| 2021-12-31 | $180.08 Million | -- |
About CERo Therapeutics Holdings, Inc. Common Stock
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.